@article{ATM29775,
author = {Hideaki Miyake},
title = {Cytoreductive nephrectomy following treatment with anti-vascular endothelial growth factor-targeted agents: is it surgically safe?},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 8},
year = {2019},
keywords = {},
abstract = {In the era of cytokine therapy, 2 prospective randomized clinical trials (RCTs) demonstrated significantly more superior overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients receiving cytoreductive nephrectomy followed by interferon-α (IFN-α) than of those treated with IFN-α alone (1,2); therefore, it has been recognized as a standard therapeutic approach for mRCC patients to perform cytoreductive nephrectomy prior to the introduction of systemic therapy.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/29775}
}